Note: In each pair of percentages the Humira value is first and the ENTYVIO value second, as the sentence states. The 383 patients match the ENTYVIO arm of VARSITY; the efficacy page lists 386 patients in the Humira arm.
Note: Table 2 pools the ulcerative colitis trials (UC Trials I and II) with the Crohn's disease trials (CD Trials I and III); the label gives ulcerative colitis rates separately only for any and serious adverse reactions, in the first passage. Table 2 columns are ENTYVIO IV (N=1434) and placebo (N=297).
How common are injection site reactions with the Entyvio Pen?
Applies to Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses
Note: The long-term safety study had no comparator arm and enrolled patients with ulcerative colitis or Crohn's disease; the page presents its exposure-adjusted incidence rates in a figure whose values are not in the page text. The label sentence on serious infections follows the pooled ulcerative colitis and Crohn's disease trial data and does not name the source of the 48-month data.